Cysteine cathepsins and extracellular matrix degradation

被引:248
作者
Fonovic, Marko [1 ,2 ]
Turk, Boris [1 ,2 ,3 ]
机构
[1] Jozef Stefan Inst, Dept Biochem Mol & Struct Biol, SI-1000 Ljubljana, Slovenia
[2] Ctr Excellence Integrated Approaches Chem & Biol, SI-1000 Ljubljana, Slovenia
[3] Univ Ljubljana, Fac Chem & Chem Technol, Ljubljana 61000, Slovenia
来源
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS | 2014年 / 1840卷 / 08期
关键词
Cathepsin; Extracellular matrix; Lysosome; Collagen; Osteoporosis; Glycosaminoglycan; ABDOMINAL AORTIC-ANEURYSMS; PH-INDUCED INACTIVATION; HUMAN PROCATHEPSIN B; PROTEASE ACTIVITY; CRYSTAL-STRUCTURE; K INHIBITOR; MOUSE MODEL; RHEUMATOID-ARTHRITIS; POSTMENOPAUSAL WOMEN; CANCER PROGRESSION;
D O I
10.1016/j.bbagen.2014.03.017
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Cysteine cathepsins are normally found in the lysosomes where they are involved in intracellular protein turnover. Their ability to degrade the components of the extracellular matrix in vitro was first reported more than 25 years ago. However, cathepsins were for a long time not considered to be among the major players in ECM degradation in vivo. During the last decade it has, however, become evident that abundant secretion of cysteine cathepsins into extracellular milieu is accompanying numerous physiological and disease conditions, enabling the cathepsins to degrade extracellular proteins. Scope of view: In this review we will focus on cysteine cathepsins and their extracellular functions linked with ECM degradation, including regulation of their activity, which is often enhanced by acidification of the extracellular microenvironment, such as found in the bone resorption lacunae or tumor microenvironment. We will further discuss the ECM substrates of cathepsins with a focus on collagen and elastin, including the importance of that for pathologies. Finally, we will overview the current status of cathepsin inhibitors in clinical development for treatment of ECM-linked diseases, in particular osteoporosis. Major conclusions: Cysteine cathepsins are among the major proteases involved in ECM remodeling, and their role is not limited to degradation only. Deregulation of their activity is linked with numerous ECM-linked diseases and they are now validated targets in a number of them. Cathepsins Sand K are the most attractive targets, especially cathepsin K as a major therapeutic target for osteoporosis with drugs targeting it in advanced clinical trials. General significance: Due to their major role in ECM remodeling cysteine cathepsins have emerged as an important group of therapeutic targets for a number of ECM-related diseases, including, osteoporosis, cancer and cardiovascular diseases. This article is part of a Special Issue entitled Matrix-mediated cell behaviour and properties. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:2560 / 2570
页数:11
相关论文
共 221 条
[1]   Cathepsin L is responsible for processing and activation of proheparanase through multiple cleavages of a linker segment [J].
Abboud-Jarrous, Ghada ;
Atzmon, Ruth ;
Peretz, Tamar ;
Palermo, Carmela ;
Gadea, Bedrick B. ;
Joyce, Johanna A. ;
Vlodavsky, Israel .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (26) :18167-18176
[2]   Inflammation in osteoarthritis [J].
Goldring, Mary B. ;
Otero, Miguel .
CURRENT OPINION IN RHEUMATOLOGY, 2011, 23 (05) :471-478
[3]   Cathepsin B activity regulation - Heparin-like glycosaminoglycans protect human cathepsin B from alkaline pH-induced inactivation [J].
Almeida, PC ;
Nantes, IL ;
Chagas, JR ;
Rizzi, CCA ;
Faljoni-Alario, A ;
Carmona, E ;
Juliano, L ;
Nader, HB ;
Tersariol, ILS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (02) :944-951
[4]   Effects of cathepsin K deficiency on intercellular junction proteins, luminal mucus layers, and extracellular matrix constituents in the mouse colon [J].
Arampatzidou, Maria ;
Schuette, Andre ;
Hansson, Gunnar C. ;
Saftig, Paul ;
Brix, Klaudia .
BIOLOGICAL CHEMISTRY, 2012, 393 (12) :1391-1403
[5]   Cathepsin B in osteoarthritis:: Uncontrolled proteolysis in the wrong place [J].
Baici, A ;
Lang, A ;
Zwicky, R ;
Müntener, K .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2005, 34 (06) :24-28
[6]   Therapeutic dosing of an orally active, selective cathepsin S inhibitor suppresses disease in models of autoimmunity [J].
Baugh, Mark ;
Black, Darcey ;
Westwood, Paul ;
Kinghorn, Emma ;
McGregor, Kieran ;
Bruin, John ;
Hamilton, William ;
Dempster, Maureen ;
Claxton, Christopher ;
Cai, Jiaqiang ;
Bennett, Jonathan ;
Long, Clive ;
Mckinnon, Heather ;
Vink, Paul ;
den Hoed, Leontien ;
Gorecka, Monika ;
Vora, Kalpit ;
Grant, Ethan ;
Percival, M. David ;
Boots, A. Mieke H. ;
van Lierop, Marie-Jose .
JOURNAL OF AUTOIMMUNITY, 2011, 36 (3-4) :201-209
[7]   Identification of peptide fragments generated by digestion of bovine and human osteocalcin with the lysosomal proteinases cathepsin B, D, L, H, and S [J].
Baumgrass, R ;
Williamson, MK ;
Price, PA .
JOURNAL OF BONE AND MINERAL RESEARCH, 1997, 12 (03) :447-455
[8]   Inhibition of cysteine cathepsin protease activity enhances chemotherapy regimens by decreasing tumor growth and invasiveness in a mouse model of multistage cancer [J].
Bell-McGuinn, Katherine M. ;
Garfall, Alfred L. ;
Bogyo, Matthew ;
Hanahan, Douglas ;
Joyce, Johanna A. .
CANCER RESEARCH, 2007, 67 (15) :7378-7385
[9]  
Biniossek ML, 2011, J PROTEOME RES, V10, P5363, DOI 10.1021/pr200621z
[10]   Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes [J].
Blum, Galia ;
von Degenfeld, Georges ;
Merchant, Milton J. ;
Blau, Helen M. ;
Bogyo, Matthew .
NATURE CHEMICAL BIOLOGY, 2007, 3 (10) :668-677